Detail
| LncRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 Sequence |
| Ensembl | ENSG00000240498 |
| RefSeq | NR_003529 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 M8140/3 |
| Methods | qPCR, Western blot etc. |
| Sample | LAD tissues, cell line A549/Taxol |
| Expression Pattern | up-regulated |
| Function Description | Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2. |
| Pubmed ID | 28402932 |
| Year | 2017 |
| Title | The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells |
| External Links |
| Links for ANRIL | GenBank HGNC lncrnadb Noncode |
| Links for lung adenocarcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.